A B S T R A C T These studies were carried out to investigate the mechanism of neutralization of purified Epstein-Barr virus (EBV) simplex I (HSV-1) absorbed the EBV ELISA reactivity and EBV-neutralizing activity of nonimmune sera, whereas another member of the herpesvirus group, cytomegalovirus, was inactive in this regard. HSV-1 was quantitatively more efficient than EBV in absorbing reactivity, a finding that indicates that the antibody has a higher affinity for HSV-1 than for EBV. Further absorption studies indicated that the cross-reaction occurred in both directions as EBV also absorbed HSV-1 reactive antibodies as tested in an HSV-1 ELISA. EBV was also less efficient than HSV-1 in absorbing reactivity with HSV-1. A serum lacking detectable antibodies.to both EBV and HSV-1 failed to neutralize EBV. These studies cumulatively indicate that fresh serum from EBV nonimmune individuals neutralizes EBV by the combined action of a previously undescribed cross-reacting antibody apparently elicited by HSV-1 and Cl, C4, C2, and C3 of the classical complement pathway.
INTRODUCTION Epstein-Barr virus (EBV)' infection in man usually
occurs early in life and is not generally accompanied by apparent clinical diseases (1) . If the initial contact ' Abbreviations used in this paper: CBL, cord blood leukocytes: CBL(EBV+), Epstein-Barr virus transformed cord blood cell line; CMV, cytomegalovirus; EBNA, Epstein-Barr nuclear antigen; EBV, Epstein-Barr virus; ELISA, enzymelinked immunoabsorbent assay; HSV-1, herpes simplex I virus; PAP, purified alternative pathway proteins; PBS, phosphate-buffered saline, pH 7.4; VBS+", veronal-buffered saline containing 1 mM Mg++ and 2.5 mM Ca++; VCA, viral capsid antigen; VSV, vesicular stomatitis virus; Z, reciprocal serum dilution giving 63% hemolysis of antibody sensitized erythrocytes.
with EBV is delayed until adolescence or adulthood, the virus causes infectious mononucleosis in a significant proportion of individuals (2) . In most cases this disorder is self-limiting, but it can progress to a fatal lymphoproliferative disease in immune-deficient individuals (3, 4) . In addition, EBV is an oncogenic agent in certain nonhuman primates (5) and is a prime candidate for a human cancer virus (6, 7) .
Host defense against EBV includes cellular immune mechanisms that suppress B lymphocytes infected with EBV (8, 9) , humoral antibodies that inactivate EBV before infection (7, 10) , as well as nonspecific humoral factors (11, 12) that may also play an important role in limiting the spread of the virus.
Approximately 80-90% of adult individuals possess these immunologic defense mechanisms indicative of previous EBV infection (13) . However, the remaining population lack detectable EBV antibodies and specific cytotoxic T cells. Such individuals have presumably not been exposed to EBV and would be expected to lack immunity to the virus. We were thus surprised to find that fresh serum from one such individual efficiently neutralized purified EBV in vitro (14) . The observation that heating (56°C, 30 min), or chelation of metals in the serum with EDTA abrogated the neutralizing activity suggested complement involvement. Subsequent studies have revealed that sera from other individuals lacking antibodies to viral capsid antigens (VCA) and Epstein-Barr nuclear antigens (EBNA) EBV also neutralized the virus. The following study was undertaken to determine the mechanisms involved in EBV inactivation by nonimmune sera.
METHODS
Isolation and quantitation of EBV, herpes simplex virus-1, cytomegalovirus, and vesicular stomatitis virus. The transforming strain of EBV was isolated from supernates of 12-O-tetracanoyl-phorbol-13-acetate stimulated B95-8 marmoset lymphoblastoid cells by sedimentation on dextran T-10 gradients as previously described (14) . A single modification in the procedure was the initial concentration of the supernatant fluids by Pellicon (Millipore Corp., Bedford, MA) cassette (108 mol wt) filtration. EBV preparations were devoid of significant cellular contamination as judged by transmission electron microscopy (14) . Tritium-labeled EBV was obtained by addition of [3H]thymidine to B95-8 cultures as previously described (14) . Herpes simplex virus I (HSV-1) was produced in hamster kidney cells and purified on 15-50% (wt/wt) Renograffin (E. R. Squibb & Co., Princeton, NJ) gradients. Cytomegalovirus (CMV), strain AD169, was produced in human embryonic skin fibroblasts.
EBV and HSV-1 were quantitated by determination of the DNA content of each virus preparation as follows. Aliquots of virus were disrupted by incubation (37°C, 10 min) in 0.3 N NaOH and the released DNA was detected spectrophotometrically at 260 nm. The concentration of DNA was then calculated to determine the number of virus particles using the extinction coefficient of DNA in NaOH (e = 37.0) and the number of particles determined using a molecular weight of 1.1 X 108 for EBV (15) Hospital, Duarte, CA) from a patient with nasopharyngeal carcinoma (VCA 1:5,120). The three types of sera noted above are referred to as normal nonimmune, normal immune, and hyperimmune in this paper. Serum from an agammaglobinemic patient contained 3.8 Ag/ml of serum IgG and no detectable IgM or IgA (<70 ,ug/ml). This serum had normal complement activity after reconstitution with purified Clq at 70 lAg/ml. The IgG fractions of these sera were prepared by ammonium sulfate precipitation followed by DEAE-cellulose column chromatography. The purified IgG fractions were sterile filtered and stored at concentrations of 10-35 mg/ml in phosphate-buffered saline (PBS) at -700C.
Complement (C) components and reagents. Human Clq (20) , Clr (21) , Cls (22) , C4 (23), C2 (24), C3 (25) , and Cl inhibitor (26) were isolated from human serum by published methods. Component Cl was assembled with purified Clq, Clr, and Cls at equimolar ratios to achieve a hemolytic titer equivalent to that of serum Cl (1Z = 80,000). The purified reassembled classical pathway included Clq (70,ug/ml), Clr (34 Ag/ml), Cls (31 Ag/ml), C4 (600 .ug/ml), C2 (25 gg/ml), and C3 (1.2 mg/ml), which were assembled to achieve the level of serum C components. The purified alternative proteins (PAP) assembled at serum concentration included Factor B (200 ug/ml), C3 (1, 200 ,ug/ml), factor D (2 ,ug/ml), properdin (20,ug/ml), C3bINA (I) (34 ,g/ml), and BIH (H) (470 ,g/ml) as previously described (27) . The PAP proteins were assayed for activity by lysis of rabbit erythrocytes (RaE 50 Al of PBS were added (12.5 to 100 ng/well) and after incubation and washing as described above, 50 AI of glucoseoxidase conjugated goat anti-human F(ab')2 (kindly provided by Rov Johnson) was added. After a second incubation for 60 min, the reaction was developed with the substrate as described above.
Neutralization and viral infectivity assays. EBV infectivity was assayed by the ability of the virus to stimulate DNA synthesis in CBL as measured by incorporation of [3H]thymidine (29) . This assay can be used to quantitate the amount of tranforming virus in a given sample since only viable EBV will stimulate DNA synthesis in neonatal B cells (14) . Thymidine incorporation was determined 4 d after infection rather than at 10-14 d as previously used (14) . A linear relationship also prevails between incorporation and purified EBV input 4 d after infection. Incorporation on day 4 represented specific viral activity and not a nonspecific mitogenic effect as immune, but not nonimmune, human anti-EBV IgG completely abrogated incorporation. Viral neutralization assays by colony formation (14) also correlate with the response at day 4. Complement proteins and serum reagents were usually sterile filtered before initiating neutralization experiments. Equal volumes of virus (7.5 X 106 particles in 75 ,ul) and C proteins (in VBS++ buffer) in concentrations equivalent to those present in undiluted normal sera were incubated at 37°C for 45 min. Next, 2 X 105 CBL were added and incubation continued for 60 min at 37°C in a 5% CO2 humidified incubator. The CBL were then washed with RPMI media, plated in microtiter plates, and pulsed with 2 gCi of [3H]thymidine 4 Absorption of nonimmune IgG and serum with virus. Purified EBV, HSV-1, CMV, or VSV were used to absorb either serum or purified IgG obtained from individuals nonimmune to EBV. 50 Al of EBV, CMV, HSV-1, or VSV, in amounts specified in the text, were added to 50 ytl of whole serum or purified nonimmune IgG (90 Htg) and the mixtures allowed to incubate overnight at 40C. Subsequently, the IgGvirus complexes were removed by airfuge ultracentrifugation (Beckman Instruments, Inc., Palo Alto, CA) and the supernatant analyzed for EBV neutralizing activity in the presence of complement as described above. The supernatant was also analyzed for ELISA reactivity to EBV or HSV-1. Controls included nonimmune IgG preincubated with either VSV or PBS.
RESULTS
Examination of normal nonimmune, normal immune and hyperimmune human sera for the presence of EBV antibody by ELISA assay. As previously noted, a fresh normal nonimmune human serum lacking both VCA and EBNA antibodies to EBV was found to neutralize the virus (14) . Because -10% of the population lacks these antibodies (13) , it was of interest to determine whether sera from other such individuals Neutralization of Epstein PwipfocA Dtion of Swum FIGURE 1 ELISA assay for detection of IgG (-0) and IgM (----0) antibodies to EBV in the serum of (A) normal nonimmune, (B) normal immune, and (C) nasopharyngeal carcinoma (hyperimmune) sera. The normal nonimmune serum is the nonimmune serum I in Table I and the normal immune serum is the immune in Table I. IC and strated that normal nonimmune human sera contained low levels of IgG antibody reactive with EBV.
Antibody and complement requirements for EBV neutralization by nonimmune sera. Studies were carried out to determine whether antibody, antibody and complement, or complement alone was required for EBV neutralization by normal nonimmune sera. As expected from the heat labile nature of EBV neutralization by nonimmune sera, physiological concentrations of isolated IgG from such sera did not neutralize EBV (Table II) . Nevertheless IgG was required for neutralization as an IgG-depleted immune serum (not shown) and an agammaglobinemic serum (Table I) , both containing adequate C levels, failed to neutralize EBV. Reconstitution of these sera with purified immune IgG fully restored this activity. Further studies with C component-depleted nonimmune serum were carried out to determine the complement pathway used for EBV neutralization. Nonimmune serum depleted of both Clq and factor D failed to significantly neutralize EBV (Table II) . Purified Clq significantly restored neutralizing activity to the serum. Factor D neither restored neutralizing activity to the depleted serum nor potentiated the neutralization observed with restoration with Clq. The above studies indicated requirements for both IgG and the classical pathway for EBV neutralization by nonimmune human serum.
The complement proteins required for neutralization were examined in the following studies. Purified (27) . Functional activity of the mixtures used here was verified by showing full activity in lysing rabbit erythrocytes. The PAP was, however, devoid of the ability to neutralize EBV, regardless of the presence or absence of nonimmune IgG (Table I1I) .
To determine whether completion of the complement sequence was required for neutralization, purified EBV was reacted with C8-depleted nonimmune human serum. C8-depleted serum neutralized EBV as well as untreated serum (Table IV) indicating that the assembled C5b-9 attack complex was not required and therefore lysis was not necessary for neutralization of EBV. These studies showed that EBV was efficiently neutralized by nonimmune human IgG present in normal nonimmune human serum together with the first four reacting classical pathway components Cl, C2, 260- (14) . There was no evidence of significant aggregation or viral lysis. In contrast, EBV reacted with nonimmune serum followed by anti-C3 was pelleted to the bottom of the gradient indicating the presence of a C3 product on the virus envelope (Fig. 3B) . Anti-C3 did not pellet virus preincubated with EDTA or Mg++-EGTA-treated nonimmune serum (Fig. 3C, 3D ), findings consistent with C3 (b, bi, or d) deposition exclusively via the classical pathway. IgG was also required for this reaction since virus preincubated with IgG-depleted immune serum was not pelleted by anti-C3 (Fig. 3E) . This property was reconstituted by the addition of physiological levels of normal immune IgG to the serum (Fig. 3F) .
Analysis of the viral specificity of the IgG antibody in nonimmune serum. Although not previously described, it was considered likely that the IgG in nonimmune sera reactive with EBV represented cross-reacting antibody elicited by other herpesviruses. The most likely candidates were considered to be HSV-1 Percent of Gradient FIGURE 3 Demonstration of C3 deposition on EBV by nonimmune human serum. Purified 3H-labeled EBV was incubated with (A, B) nonimmune serum, (C) nonimmune serum + EDTA, (D) nonimmune serum + Mg++-EGTA, (E) immune serum depleted of IgG, (F) IgG-depleted immune serum reconstituted with IgG. After a second incubation with anti-human C3 except sample (A), which was incubated with buffer, the samples were ultracentrifuged on 5-30% dextran T-10 gradients. Fractions were then assayed for radioactivity. The direction of sedimentation indicated by the arrow, is to the left. or CMV. Since three of the four nonimmune sera had moderate to elevated ELISA titers to HSV-1 (data not shown), we first examined the relationship of the antibody to HSV-1. Isolated IgG from normal nonimmune serum (1 in Table I ) was absorbed with varying amounts of purified EBV, HSV-1, or VSV (as a control). The absorbed IgG was then assayed with purified Cl, C4, C2, and C3 for EBV neutralization (Fig. 4, upper  panel) and for binding to EBV in the ELISA (Fig. 4 , lower panel). As can be seen, both EBV and HSV-1 absorbed reactivity, but HSV-1 was quantitatively more efficient than EBV in absorbing both the EBVneutralizing and EBV-binding activity of nonimmune IgG. VSV, the control, failed to absorb either reactivity. In other experiments we were unable to absorb the neutralizing and EBV ELISA reactivity of nonimmune serum with equivalent amounts of CMV (data not shown).
Cross-reactivity between IgG antibodies to EBV and HSV-1 in nonimmune sera was also observed in the reciprocal experiment using an HSV-1 ELISA. Purified HSV-1 and to a lesser extent EBV, but not CMV absorbed a significant proportion of IgG antibodies reactive with HSV-1 from the nonimmune serum (Fig. 5 ). The above data together indicate that the primary antigenic reactivity of the nonimmune IgG is with HSV-1.
Virus used for Absorption (Virions x 1 06) FIGURE 4 Analysis of the viral specificity of the nonimmune IgG reactive with HSV-1 and with EBV. Purified nonimmune IgG (90 Mg) was preabsorbed with varying amounts (1.25 X 106 to 1 X 107 virions) of isolated EBV (0 *), HSV-1 (A A) or VSV (U U) prior to being assayed undiluted for residual EBV neutralizing activity in the presence of purified Cl, C4, C2, and C3 (upper panel) or for EBV ELISA reactivity (lower panel).
A serum from a 4-month-old infant (nonimmune 4) lacking detectable reactivity with either EBV or HSV-1 (Table V) was examined for ability to neutralize EBV. Since this serum lacked adequate complement function the same agammaglobinemic serum as described in Table I , which lacks neutralizing activity, was added as a complement source. As seen in Table  V this nonimmune serum failed to neutralize EBV in the presence of the agammaglobinemic serum. However, significant neutralization was achieved with the addition of IgG from another nonimmune (1) . These findings indicate that both cross-reacting antibody and complement are needed for neutralization of EBV. Although the mechanism by which complement, together with the nonimmune antibody, induces neutralization was not directly addressed in these studies, it is evident that neutralization is not due to complement-dependent lysis, since C8-depleted serum effectively neutralized EBV. Serum lacking C8 does not permit formation of the C5b-9 membrane attack complex required for lysis. Furthermore, the density gradient ultracentrifugation studies with 3H-labeled EBV and nonimmune serum did not provide evidence of viral disruption. The density gradient studies also showed that complement did not neutralize EBV by inducing viral aggregation, as occurs with some viruses (31) . Viral aggregation reduces the net number of infectious particles and thus produces an apparent decrease in viral titer, or neutralization. Complement most likely neutralizes EBV by contributing protein, primarily C3 products, to the virus envelope. Since C3 products are deposited and covalently bind to surfaces in a spatial distribution surrounding each C-activating immune complex, it is likely that some of the C3 fragment molecules become bound to viral structures involved in attachment to and/or penetration of B lymphocytes. This mechanism of complement-dependent viral neutralization has been observed with other viruses and is most likely the mechanism of IgM and complement-mediated inactivation of avian infectious bronchitis virus (32) , HSV (33) (34) (35) , Newcastle disease virus (36), equine arteritis virus (37), vesicular stomatitis virus (38) , and vaccinia virus (39) . Studies with complement components with some of these viruses show that herpes simplex I (33) and equine arteritis viruses (37) can be neutralized by antibody together with Cl and C4 but these viruses and also Newcastle disease virus (36) , vesicular stomatitis virus (38) , and vaccinia virus (39) are more efficiently neutralized in the presence of Cl, C4, C2, and C3. Several viruses have been reported to be neutralized by IgG and complement including the herpesviruses, CMV (40) , and equine herpesvirus I (41), however, the complement requirements for these effects remain to be investigated.
It is well documented that lymphoblastoid cells bearing the EBV genome activate the alternative complement pathway (42) and under certain conditions undergo lysis (43, 44) . The ability to activate the alternative pathway correlates with some evidence of the presence of EBV genome in the cells (42 Although the present studies have not conclusively demonstrated that the antibody detected in normal nonimmune sera in the EBV ELISA has the same spec-ificity as the lgG antibody involved in the neutralization reaction, this is probable for the following three reasons. There was a correlation between the two tests with low or high reactivities in the ELISA being reflected in comparable reactivity in the neutralization test. Both the EBV ELISA and neutralizing activities were absorbed with intact EBV (Fig. 4) , and therefore the IgG antibody participating in both reactions is directed against viral surface structures. Finally, both reactivities were also absorbed by HSV-1, indicating that the two assays involve an IgG antibody that is cross-reactive with EBV.
The viral antigen reactive with the IgG antibody in nonimmune human sera and detected in the ELISA and neutralization tests is not the VCA or EBNA antigens associated with EBV, as is evident from the lack of correlation between these reactivities in Table 1 (46) .
The specificity of the IgG antibody present in the nonimmune sera that reacted with EBV in the ELISA and, together with Cl, C4, C2, and C3, participated in its neutralization, was examined in absorption studies. It was considered most likely that the antibody was elicited by infection with another herpesvirus and cross-reacted with EBV. Absorption studies showed that HSV-1 as well as EBV absorbed the antibody reactive with EBV in the ELISA and in the neutralization reaction whereas neither CMV, another herpesvirus, nor VSV, as a control, failed to do so (Fig. 4) . HSV-1 was quanititatively more efficient than EBV in absorbing the EBV-reactive antibody. The cross-reaction extended also in the reverse direction in that HSV-1 and EBV, but again not CMV, absorbed the antibody reactive with HSV-1 as tested in an HSV-1 ELISA (Fig.  5) . Again, the antibody was more readily absorbed by HSV-l than EBV. These studies indicate that the primary specificity of the antibody is almost certainly directed against HSV-1 and that the cross-reaction does not include another human herpesvirus, CMV. The (MV results document the specificity of the absorption studies. Furthermore, since CMV (47) like HSV-1 (48) , has Fc receptors but fails to absorb reactivity, the ab)sorption results cannot be explained by non-specific depletion of immunoglobulin by the Fc receptors.
EBV and HSV-1, although both herpesviruses, have not beent previously reported to elicit cross-reacting antibodies. Among the relatively few reported instances of cross-reactive herpesvirus proteins is the CP-1 (gp52) envelope glycoprotein of HSV-1 and HSV-2 (49). Although we do not yet know the extent of crossreactivity of the IgG antibody involved in EBV neutralization with other herpesviruses, we found that CMV did not absorb the IgG antibody reactive with EBV in nonimmune serum. As has been true in the past few years with other families of viruses, it is probable that additional cross-reactions and other evidence of relatedness will become apparent as more sensitive and different assay systems are utilized, such as the ELISA and complement-dependent neutralization reactions used in this study.
In the present studies, fresh undiluted human serum from normal EBV nonimmune individuals neutralized i107 virions of EBV/ml of serum. Thus, this complement dependent reaction neutralizes EBV as well as does immune human serum. Since infectious mononucleosis is known to only develop in individuals lacking antibody (noncomplement requiring) to EBV (50), it is not unlikely that the complement-requiring crossreactive antibody to herpes simplex virus also prevents EBV-induced disease. In this regard, it would be of interest to follow a number of normal nonimmune individuals having EBV cross-reacting antibodies to determine whether they are immune to EBV infection and thus fail to convert to EBV positivity.
